How long will the investor exuberance driving public offerings of biotech companies last? Brady Huggett investigates.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Author information
Authors and Affiliations
Supplementary information
Supplementary Text and Figures
Supplementary Table 1 (XLSX 14 kb)
Rights and permissions
About this article
Cite this article
Huggett, B. Burning bright. Nat Biotechnol 31, 1068–1071 (2013). https://doi.org/10.1038/nbt.2766
Published:
Issue date:
DOI: https://doi.org/10.1038/nbt.2766
This article is cited by
-
Biotech's wellspring: the health of private biotech in 2013
Nature Biotechnology (2014)
